SUBSEQUENT EVENTS	9 Months Ended
Sep. 30, 2021
SUBSEQUENT EVENTS
NOTE 22 - SUBSEQUENT EVENTS	NOTE 22 – SUBSEQUENT EVENTS On October 7, 2021 and October 19, 2021, the Company received $0.05 million and $0.02 million, respectively, from one of the Company’s board members (“Second Board Investor”) in exchange for two promissory notes. Both the Company and Second Board Investor agreed to negotiate the terms of the promissory notes and as of the filing date of this report, the Company and Second Board Investor are still negotiating the terms of the promissory notes. On October 15, 2021, the Company received $0.3 million as an initial deposit from a distribution company (“Distributor”) for the distribution rights of the Company’s sildenafil OTF product (“Distribution Rights”). As of the date of this report, the Company and the Distributor are still negotiating a definitive agreement to finalize the terms of the Distribution Rights per territory. On October 27, 2021, the Company received $0.3 million from an investment company (“Investor”) in exchange for a promissory note. Both the Company and Investor agreed to negotiate the terms of the promissory notes and as of the filing date of this report, the Company and Investor are still negotiating the terms of the promissory notes. On October 30, 2021, the Series B Note matured and is due according to its terms (see Note 13). On November 3, 2021 the Company received an Event of Default Redemption Notice from the Investor citing non-payment of the maturity amount, and requesting payment of a default amount, including penalties, of $9.1 million by November 10, 2021. The Company reviewed and does not agree with the amount due. As of the filing date of this report, the Company is negotiating an extension of the maturity date and the amount due on terms satisfactory to the Company. There can be no guaranty that the Company will be successful in this effort in which case the Investor may endeavor to exercise its remedies.

SUBSEQUENT EVENTS

9 Months Ended

Sep. 30, 2021

NOTE 22 – SUBSEQUENT EVENTS

On October 7, 2021 and October 19, 2021, the Company received $0.05 million and $0.02 million, respectively, from one of the Company’s board members (“Second Board Investor”) in exchange for two promissory notes. Both the Company and Second Board Investor agreed to negotiate the terms of the promissory notes and as of the filing date of this report, the Company and Second Board Investor are still negotiating the terms of the promissory notes.

On October 15, 2021, the Company received $0.3 million as an initial deposit from a distribution company (“Distributor”) for the distribution rights of the Company’s sildenafil OTF product (“Distribution Rights”). As of the date of this report, the Company and the Distributor are still negotiating a definitive agreement to finalize the terms of the Distribution Rights per territory.

On October 27, 2021, the Company received $0.3 million from an investment company (“Investor”) in exchange for a promissory note. Both the Company and Investor agreed to negotiate the terms of the promissory notes and as of the filing date of this report, the Company and Investor are still negotiating the terms of the promissory notes.

On October 30, 2021, the Series B Note matured and is due according to its terms (see Note 13). On November 3, 2021 the Company received an Event of Default Redemption Notice from the Investor citing non-payment of the maturity amount, and requesting payment of a default amount, including penalties, of $9.1 million by November 10, 2021. The Company reviewed and does not agree with the amount due. As of the filing date of this report, the Company is negotiating an extension of the maturity date and the amount due on terms satisfactory to the Company. There can be no guaranty that the Company will be successful in this effort in which case the Investor may endeavor to exercise its remedies.